公开(公告)号：MA34907B1

公开(公告)日：2014-02-01

申请号：MA36181

申请日：2013-08-07

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BAKER TERENCE SEWARD ,  LAWSON ALASTAIR DAVID GRIFFITHS

IPC: C07K16/24

Abstract: Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques à la fois de IL-17A et IL-17F, les utilisations thérapeutiques de ces molécules d'anticorps et des procédés d'obtention des dites molécules.

公开(公告)号：SG191906A1

公开(公告)日：2013-08-30

申请号：SG2013052741

申请日：2012-01-11

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BAKER TERENCE SEWARD ,  LAWSON ALASTAIR DAVID GRIFFITHS

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：ZA200907385B

公开(公告)日：2011-04-28

申请号：ZA200907385

申请日：2009-10-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： TYSON KERRY LOUISE ,  SHOCK ANTHONY ,  BROWN DEREK THOMAS ,  TAYLOR FREDERICK R ,  SU LIHE ,  HSU YEN-MING ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  ADAMS RALPH ,  POPPLEWELL ANDREW GEORGE ,  BURKLY LINDA C ,  ROBINSON MARTYN KIM

Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：HK1125113A1

公开(公告)日：2009-07-31

申请号：HK09102389

申请日：2009-03-12

Applicant: UCB PHARMA SA

Inventor： GELINAS RICHARD EVAN ,  SINGHAL MITRA CHOUDHURY ,  ZHANG YI ,  POPPLEWELL ANDREW GEORGE ,  ADAMS RALPH

IPC: C07K20060101

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：AU2008232409A1

公开(公告)日：2008-10-02

申请号：AU2008232409

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： GARBER ELLEN A ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TAYLOR FREDERICK R ,  BURKLY LINDA C ,  HSU YEN-MING ,  FERRANT-ORGETTAS JANINE L ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  SU LIHE ,  ADAMS RALPH ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：NO20083066A

公开(公告)日：2008-09-08

申请号：NO20083066

申请日：2008-07-08

Applicant: UCB PHARMA SA

Inventor： GELINAS RICHARD EVAN ,  SINGHAL MITRA CHOUDHURY ,  ZHANG YI ,  POPPLEWELL ANDREW GEORGE ,  ADAMS RALPH

IPC: C07K16/24 ,  A61K39/395 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  C07K16/248 ,  C07K2316/96 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/11

公开(公告)号：ECSP088613A

公开(公告)日：2008-08-29

申请号：ECSP088613

申请日：2008-07-07

Applicant: UCB PHARMA SA

Inventor： POPPLEWELL ANDREW GEORGE ,  GELINAS RICHARD EVAN ,  SINGHAL MITRA CHOUDHURY ,  ZHANG YI ,  ADAMS RALPH

Abstract: La invención se relaciona con las moléculas de anticuerpo que tienen especificidad para determinantes antigénicos de la IL-6, los usos terapéuticos de las moléculas de anticuerpo y los métodos para producir dichas moléculas de anticuerpo.

公开(公告)号：AU2007311689A1

公开(公告)日：2008-04-24

申请号：AU2007311689

申请日：2007-10-18

Applicant: UCB PHARMA SA

Inventor： RAPECKI STEPHEN EDWARD ,  ADAMS RALPH ,  POPPLEWELL ANDREW GEORGE

IPC: A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K16/24 ,  C12N15/13

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：PE20080214A1

公开(公告)日：2008-04-08

申请号：PE2007000825

申请日：2007-06-26

Applicant: UCB PHARMA SA

Inventor： RAPECKI STEPHEN EDWARD ,  POPPLEWELL ANDREW GEORGE ,  ADAMS RALPH

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/24 ,  C12N5/20 ,  C12N15/13

Abstract: SE REFIERE A UN ANTICUERPO QUE INHIBE LA ACTIVIDAD DE LA INTERLEUQUINA 17 (IL-17) QUE COMPRENDE: A) UNA CADENA PESADA CUYO DOMINIO VARIABLE SE ENCUENTRA EN LA SEC ID Nº: 1 PARA CDR-H1, SEC ID Nº: 2 PARA CDR-H2 Y SEC ID Nº: 3 PARA CDR-H3; B) UNA CADENA LIGERA CUYO DOMINIO VARIABLE SE ENCUENTRA EN LA SEC ID Nº: 4 PARA CDR-L1, SEC ID Nº: 5 PARA CDR-L2 Y SEC ID Nº: 6 PARA CDR-L3. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL ANTICUERPO. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ENFERMEDAD DE CROHN, PSORIASIS

公开(公告)号：CL2007001840A1

公开(公告)日：2008-01-18

申请号：CL2007001840

申请日：2007-06-22

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  RAPECKI STEPHEN E ,  POPPLEWELL ANDREW G

IPC: A61K39/395 ,  A61P37/00 ,  A61P43/00 ,  C07K16/24 ,  C12N5/20 ,  C12N15/13

Abstract: Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de ADN que lo codifica; vector y célula huésped que la comprenden; proceso de producción; preparación farmacéutica que lo comprende; y su uso para el tratamiento o profilaxis de patologías mediadas por il-17.